We are pleased to announce the release of the Charter for Improving Care for People Living with Chronic Lymphocytic Leukemia (CLL) – a global initiative led and endorsed by patient advocacy organisations like us, clinicians, and people living with CLL.

This Charter has been organised and funded by AstraZeneca

The Charter sets out six core principles that define what good care should look like for anyone affected by CLL. It highlights key aspects of care that are often overlooked – such as timely and accurate diagnosis, access to understandable and tailored information, shared decision-making, emotional and psychological support, and comprehensive care that addresses the full impact of the disease, including its complications and long-term effects.

The purpose of this Charter is to provide a unified, patient-centred framework that can guide improvements in CLL care around the world. It is designed to inform policy discussions, support advocacy efforts, shape national cancer plans, and serve as a benchmark for healthcare providers and systems.

Going forward, the Charter will serve as a reference point for patients, patient groups, clinicians, and decision-makers to advocate for systemic changes that ensure all people living with CLL – regardless of geography or background – receive the support, information, and care they need to live well with their diagnosis.

Please click the button below to access the Charter:

This Charter has been organised and funded by AstraZeneca and is the result of collaborative discussions initiated at the 2024 European Hematology Association Annual Conference and has since been refined through input from global patient advocates and clinical experts at the CLLAN Horizons Conference 2024 and beyond.

We believe this Charter is a big step towards supporting a better future for the CLL community.

Z4-76877 | Date of Preparation: September 2025